Rege-Pro

Rege-Pro is a biological wound dressing and regenerative therapeutic product derived from human amniotic membrane, which is processed through lyophilization (freeze-drying) and gamma irradiation for sterilization. Developed by the National Center for Radiation Research and Technology (NCRRT) under the Egyptian Atomic Energy Authority, it is utilized for the treatment of various chronic and acute wounds, including skin ulcers, psoriasis, and Dystrophic Epidermolysis Bullosa. The product functions as a biological scaffold that mimics the natural extracellular matrix (ECM), containing key structural proteins such as collagen types IV and VII, fibronectin, and laminin, which are essential for cellular adhesion and migration. Furthermore, Rege-Pro serves as a bioactive reservoir of endogenous growth factors, including Epidermal Growth Factor (EGF) and Transforming Growth Factor-beta (TGF-β), which promote epithelialization, reduce inflammatory markers, and facilitate the formation of granulation tissue. It is available as a dry membrane patch or in a gel-based formulation, offering a biocompatible alternative for tissue repair and ocular surface reconstruction.

Brand names

Rege-ProREGE proREGE pro gel

Other names

Dried human amniotic membrane dressingIrradiated human amniotic membraneREGE pro dressingFreeze-dried amniotic membraneFDAM